Wesana Health, WBC Partner to Study Psychedelics as Treatment for TBIs

May 25, 2021 14:20:52

Daniel Carcillo retired from the National Hockey League in 2015, after nine seasons in the game. He had been diagnosed with several concussions and had struggled with insomnia, depression, anxiety, headaches and even slurred speech in his professional seasons as a hockey player.

Determined to get better, Carcillo implemented lifestyle changes that included the use of psilocybin, an active ingredient found in magic mushrooms, as well as eating healthier and getting more sleep. This, he said, helped improve his overall heath tremendously.

He is now dedicating his life to helping other individuals like himself as well as athletes who have experienced traumatic brain injuries (“TBIs”). Wesana Health, which is a company Carcillo helped found in 2020, is focused on testing the use of psychedelics as a treatment for depression and anxiety for individuals who suffer from traumatic brain injuries.

The company went public on the Canadian Securities Exchange a few days ago, after which it announced a partnership with the World Boxing Council, which may provide a deeper understanding of traumatic brain injuries. Presently, there are no approved measurements, diagnostics or treatments for the condition.

The World Boxing Council partnership will enable Wesana Health to access data that the organization has acquired on TBIs in fighters that dates back to the ‘70s and highlights how the condition can cause neurological and physical changes in boxers, which may prove beneficial to the company and its research.

Wesana plans to examine this data as well as that acquired from current boxers in a bid to gain more understanding of this condition. In the future, the company hopes to recruit boxers in clinical trials involving a psychedelic formulation it is currently developing, dubbed Sana0013.

The candidate is still in its early stages of testing. Despite this, the company has already assembled an experienced clinical trial and medical team that includes chief science officer Mark Wingertzahn, who has occupied senior clinical development roles at major pharmaceutical firms such as Pfizer and GlaxoSmithKline. Additionally, the company’s chief medical officer Stephan Bart has worked as a principal investigator in more than 400 clinical trials in his career.

The company is planning on submitting an application to the FDA for its candidate as an investigational new drug by next year and hopes to recruit healthy individuals for its phase 1 trial by next year’s third quarter.  In addition to this, it hopes to get the drug formulation approved in Canada by Health Canada, the country’s health regulatory body.

Apart from this, the company also aims to help other groups that are at a high risk for traumatic brain injury, such as military veterans, the elderly, and women who have been domestic violence victims.

Advocates will be pleased to note that Wesana Health isn’t alone in moving the psychedelics industry forward. Other companies, such as Pure Extracts Technologies Corp. (CSE: PULL) (OTC: PRXTF), are deploying their plant extracts expertise in this burgeoning sector.

NOTE TO INVESTORS: The latest news and updates relating to Pure Extracts Technologies Corp. (CSE: PULL) (OTC: PRXTF) are available in the company’s newsroom at https://ibn.fm/PULL

About PsychedelicNewsWire

PsychedelicNewsWire (PNW) is a specialized content distribution company that (1) aggregates and distributes news and information on the latest developments in all aspects and advances of psychedelics and their use, (2) creates PsychedelicNewsBreaks designed to quickly update investors on important industry news, (3) leverages a team of expert editors to enhance press releases for maximum impact, (4) assists companies with the management and optimization of social media across a range of platforms, and (5) delivers unparalleled corporate communication solutions. PNW stays abreast of the latest information and has established a reputation as the go to source for coverage of psychedelics, therapeutics and emerging market opportunities. Our team of seasoned journalists has a proven track record of helping both public and private companies gain traction with a wide audience of investors, consumers, media outlets and the general public by leveraging our expansive dissemination network of more than 5,000 key syndication outlets. PNW is committed to delivering improved visibility and brand recognition to companies operating in the emerging markets of psychedelics.

To receive instant SMS alerts, text “Groovy” to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.PsychedelicNewsWire.com

Please see full terms of use and disclaimers on the PsychedelicNewsWire website applicable to all content provided by PNW, wherever published or re-published: https://www.PsychedelicNewsWire.com/Disclaimer

Do you have questions or are you interested in working with PNW? Ask our Editor

PsychedelicNewsWire (PNW)
San Francisco, California
415.949.5050 Office

PsychedelicNewsWire is part of the InvestorBrandNetwork.